Literature DB >> 35445950

Immunoglobulin G4-related coronary periarteritis: a systematic literature review with a case series.

Takanori Ito1, Sho Fukui2,3, Takayoshi Kanie4, Hiromichi Tamaki1, Masato Okada1.   

Abstract

We aimed to assess the clinical and radiological characteristics of immunoglobulin G4-related coronary periarteritis through a systematic literature review and from our case series. In the systematic literature review, we assessed English language manuscripts on immunoglobulin G4-related coronary periarteritis cases. Additionally, we identified patients with immunoglobulin G4-related coronary periarteritis at St. Luke's International Hospital in Tokyo, Japan, from 2014 to 2020. We summarized patients' demographics, immunoglobulin-G and -G4 titers, site and morphological features of the coronary lesion, and other organ involvements. We identified 38 cases from the literature and four patients from our institute. Coronary lesions were detected using coronary computed tomography in 40 (95.2%) patients. Mass-like or diffuse wall-thickening lesion was the most frequently observed type in 33 (78.6%) patients. No trends at the site of the coronary arteries were identified. Overall, 32 (76.1%) patients had multiple-organ involvement, of which the most common lesion was peri-aortitis in 21 (50.0%) patients. Ten (23.8%) patients with an isolated coronary lesion had significantly lower immunoglobulin-G4 titers than those with other organ involvements (immunoglobulin-G4: 261 [161.0, 564.0] vs. 1355.0 [320.8, 2480.0] mg/dL, p = 0.033). The wall-thickening lesions responded well to immunosuppressive treatments. Mass-like or diffuse wall-thickening on coronary computed tomography is a characteristic radiographic finding of immunoglobulin G4-related coronary periarteritis, which can occur in any branch. Immunoglobulin G4-related coronary periarteritis showed similar characteristics to other organ lesions, including its relatively low serum immunoglobulin-G4 level in patients with a single-organ disease and its high responsiveness to glucocorticoids.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Arteritis; Coronary aneurysm; Glucocorticoids; Immunoglobulins

Mesh:

Substances:

Year:  2022        PMID: 35445950     DOI: 10.1007/s10067-022-06179-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  42 in total

1.  Immunoglobulin G4-related coronary periarteritis in a patient presenting with myocardial ischemia.

Authors:  Jun Tanigawa; Masahiro Daimon; Motonobu Murai; Takahiro Katsumata; Motomu Tsuji; Nobukazu Ishizaka
Journal:  Hum Pathol       Date:  2012-03-07       Impact factor: 3.466

2.  Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011.

Authors:  Hisanori Umehara; Kazuichi Okazaki; Yasufumi Masaki; Mitsuhiro Kawano; Motohisa Yamamoto; Takako Saeki; Shoko Matsui; Tadashi Yoshino; Shigeo Nakamura; Shigeyuki Kawa; Hideaki Hamano; Terumi Kamisawa; Toru Shimosegawa; Akira Shimatsu; Seiji Nakamura; Tetsuhide Ito; Kenji Notohara; Takayuki Sumida; Yoshiya Tanaka; Tsuneyo Mimori; Tsutomu Chiba; Michiaki Mishima; Toshifumi Hibi; Hirohito Tsubouchi; Kazuo Inui; Hirotaka Ohara
Journal:  Mod Rheumatol       Date:  2012-01-05       Impact factor: 3.023

3.  The diagnostic utility of serum IgG4 concentrations in IgG4-related disease.

Authors:  Mollie N Carruthers; Arezou Khosroshahi; Tamara Augustin; Vikram Deshpande; John H Stone
Journal:  Ann Rheum Dis       Date:  2014-03-20       Impact factor: 19.103

Review 4.  IgG4-related disease.

Authors:  Terumi Kamisawa; Yoh Zen; Shiv Pillai; John H Stone
Journal:  Lancet       Date:  2014-12-04       Impact factor: 79.321

5.  Characteristics and prognosis of IgG4-related periaortitis/periarteritis: A systematic literature review.

Authors:  Mitsuhiro Akiyama; Yuko Kaneko; Tsutomu Takeuchi
Journal:  Autoimmun Rev       Date:  2019-07-16       Impact factor: 9.754

6.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

7.  Sudden cardiac death due to coronary artery involvement by IgG4-related disease: a rare, serious complication of a rare disease.

Authors:  Nimesh R Patel; Mary L Anzalone; L Maximilian Buja; M Tarek Elghetany
Journal:  Arch Pathol Lab Med       Date:  2014-06       Impact factor: 5.534

8.  Immunoglobulin G4-related multiple systemic aneurysms and splenic aneurysm rupture during steroid therapy.

Authors:  Miyu Tajima; Yukio Hiroi; Yutaka Takazawa; Hironori Muraoka; Hiroshi Iwata; Hiroshi Yamashita; Yasunobu Hirata; Ryozo Nagai
Journal:  Hum Pathol       Date:  2013-10-15       Impact factor: 3.466

9.  Immunoglobulin G4-related Coronary Periarteritis and Luminal Stenosis in a Patient with a History of Autoimmune Pancreatitis.

Authors:  Aiko Sakamoto; Tomofumi Tanaka; Kenji Hirano; Kazuhiko Koike; Issei Komuro
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

Review 10.  The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.

Authors:  Zachary S Wallace; Ray P Naden; Suresh Chari; Hyon K Choi; Emanuel Della-Torre; Jean-Francois Dicaire; Phillip A Hart; Dai Inoue; Mitsuhiro Kawano; Arezou Khosroshahi; Marco Lanzillotta; Kazuichi Okazaki; Cory A Perugino; Amita Sharma; Takako Saeki; Nicolas Schleinitz; Naoki Takahashi; Hisanori Umehara; Yoh Zen; John H Stone
Journal:  Ann Rheum Dis       Date:  2019-12-03       Impact factor: 19.103

View more
  1 in total

1.  Advantages of an alternate-day glucocorticoid treatment strategy for the treatment of IgG4-related disease: A preliminary retrospective cohort study.

Authors:  Sho Fukui; Takehiro Nakai; Satoshi Kawaai; Yukihiko Ikeda; Masei Suda; Atsushi Nomura; Hiromichi Tamaki; Mitsumasa Kishimoto; Sachiko Ohde; Masato Okada
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.